Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Double-crane Pharmaceutical To Set Up Subsidiary In Liaoning

This article was originally published in PharmAsia News

Executive Summary

Beijing Double-crane Pharmaceutical has announced plans to invest RMB 100 million ($14.6 million) to set up a wholly-owned subsidiary named Liaoning Double-crane in Liaoning province, with plans to establish a medical transfusion product line. Present transfusion packaging firms in China's northeast region are small-scale operations producing glass bottles. Plastic transfusion bags are increasingly replacing glass, showing a huge development potential and opportunity for Double-crane. Meanwhile, the company will loan RMB 62.36 million ($9.10 million) to subsidiary Beijing Wanhui Double-crane Pharmaceutical to set up a U.S. FDA-cGMP-compliant solid pharmaceutical formulation base. The move marks the corporation's first concrete step into the American and European market. (Click here for more - Chinese Language)

You may also be interested in...



TransEnterix Names New CFO, Reports Negative Q2 Earnings Amid Challenging Times

TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

CureVac Launches IPO, Adds To Big 2020 Cash Haul

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel